Eterna Therapeutics (ERNA) Institutional Ownership $0.31 -0.02 (-7.08%) Closing price 02/21/2025 04:00 PM EasternExtended Trading$0.31 -0.01 (-2.51%) As of 02/21/2025 07:39 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Ownership Stock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends Institutional Ownership Changes (13F Filings) for Eterna Therapeutics (NASDAQ:ERNA)CurrentInstitutional OwnershipPercentage70.55%Number ofInstitutional Buyers(last 12 months)3TotalInstitutional Inflows(last 12 months)$150.16KNumber ofInstitutional Sellers(last 12 months)0 Get ERNA Insider Trade Alerts Want to know when executives and insiders are buying or selling Eterna Therapeutics stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address Skip Chart & View Institutional Buying and Selling Data ERNA Institutional Buying and Selling by Quarter Eterna Therapeutics Major Shareholders & Ownership History Export to ExcelReporting DateMajor Shareholder NameShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails2/12/2025 Geode Capital Management LLC257,310$76K0.0%+1,159.2%4.756% 5/3/2024 Avidian Wealth Solutions LLC14,798$36K0.0%N/A0.274% 5/2/2024 Sippican Capital Advisors72,800$175K0.1%+34.7%1.346% 2/13/2024 Lake Street Advisors Group LLC520,996$933K0.1%N/A9.630% 1/30/2024 Sippican Capital Advisors54,050$97K0.1%+92.3%0.999% 1/1/2024 Vanguard Group Inc.24,898$54K0.0%+30.6%0.460% 10/24/2023 Sippican Capital Advisors28,100$61K0.1%+30.1%0.519% 2/1/2023 Cypress Point Wealth Management LLC94,375$304K0.5%N/A3.210% 1/31/2023 Naviter Wealth LLC79,621$387K0.1%N/A2.708% (Data available from 1/1/2016 forward) ERNA Institutional Ownership - Frequently Asked Questions Who are the largest shareholders of ERNA shares? During the previous two years, the following institutional investors and hedge funds held shares of Eterna Therapeutics shares: Lake Street Advisors Group LLC ($933K), Sippican Capital Advisors ($175K), Geode Capital Management LLC ($76K), and Vanguard Group Inc. ($54K), Avidian Wealth Solutions LLC ($36K).Learn more on ERNA's institutional investors. What percentage of Eterna Therapeutics stock is owned by institutional investors? 70.55% of Eterna Therapeutics stock is owned by institutional investors. Learn more on ERNA's institutional investor holdings. Which institutional investors have been buying Eterna Therapeutics stock? The following institutional investors have purchased Eterna Therapeutics stock in the last 24 months: Lake Street Advisors Group LLC ($521.00K), Geode Capital Management LLC ($236.88K), Sippican Capital Advisors ($51.20K), Avidian Wealth Solutions LLC ($14.80K), and Vanguard Group Inc. ($5.83K). How much institutional buying is happening at Eterna Therapeutics? Institutional investors have bought a total of 829,698 shares in the last 24 months. This purchase volume represents approximately $1.16M in transactions. Related Companies GLTO Major Shareholders APM Major Shareholders VRAX Major Shareholders CMND Major Shareholders SNGX Major Shareholders ONVO Major Shareholders ABVC Major Shareholders ALZN Major Shareholders CANF Major Shareholders ELAB Major Shareholders This page (NASDAQ:ERNA) was last updated on 2/22/2025 by MarketBeat.com Staff From Our PartnersEx-CIA Advisor: Trump 2.0 Could “Send Gold to $10,000”Experts forecast gold's price racing to $4,000… and an ex-CIA advisor predicts we'll see gold hit $10,000. ...Colonial Metals | SponsoredAlert: DOGE goes live"It's Elon's world, and the rest of us live in it." Every investor in America is trying to figure out what ...Altimetry | SponsoredElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredThis Crypto Is Set to Explode in FebruaryIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredBuy this AI Stock Before Elon’s AnnouncementWith Trump back in office, xAI is primed to become the leader in generative AI, leaving competitors in the dus...InvestorPlace | SponsoredNvidia’s Next Big Move Comes on Feb. 26Nvidia isn't the only company that benefits greatly from these earnings calls. That's because a handful of ...Weiss Ratings | SponsoredA strange twist 500 miles from WashingtonEnergy is life. And this year, it could also make national heroes out of President Trump and VP Vance. ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Eterna Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Eterna Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
